Economic analysis and implications for health policy

International Journal of Technology Assessment in Health Care

Volumn 11, Issue 2, 1995, Pages 327-344

  Ross Degnan, Dennis ^a   Soumerai, Stephen B ^a   Avorn, Jerry ^a   Bohn, Rhonda L ^a   Bright, Rosalie ^b   Aledort, Louis M ^c  

^a HARVARD MEDICAL SCHOOL   (United States)

^b CENTER FOR DRUG EVALUATION AND RESEARCH   (United States)

^c US Food and Drug Administration ^*  (Nigeria)

Author keywords

[No Author keywords available]

Indexed keywords

BLOOD CLOTTING FACTOR 8;

ARTICLE; COST BENEFIT ANALYSIS; COST EFFECTIVENESS ANALYSIS; HEALTH CARE POLICY; HEMOPHILIA; HOME CARE; HUMAN; MAJOR CLINICAL STUDY; PRODUCTIVITY; QUALITY OF LIFE; SURVIVAL TIME; TREATMENT OUTCOME;

ADULT; CHILD, PRESCHOOL; COST-BENEFIT ANALYSIS; FACTOR VIII; HEALTH POLICY; HEMOPHILIA A; HOME INFUSION THERAPY; HUMAN; INFANT; QUALITY OF LIFE; SELF CARE; SUPPORT, NON-U.S. GOV'T; SUPPORT, U.S. GOV'T, P.H.S.;

EID: 0029028419     PISSN: 02664623     EISSN: 14716348     Source Type: Journal    
DOI: 10.1017/S0266462300006930     Document Type: Article

References (40)

1. Aledort, L. M. Lesson from hemophilia (editorial). New England Journal of Medicine, 1982, 306, 607–08.
2. Aledort, L. M., Branch. I. Cost of care for hemophiliacs. In M. Hilgartner and C. Pochedley (eds.), Hemophilia in the child and adult. New York: Raven Press Ltd., 1989, 137–47.
3. Aledort, L. M., Cohen, M., Hilgartner, M. W., Lipton. R. Treatment of hemophiliacs with inhibitors: Cost and effect on blood resources. In L. Hoyer (ed.), Factor VIII inhibitors. New York: Alan R. Liss, Inc., 1984, 353–65.
4. Avorn, J. Benefit and cost analysis in geriatric care: Turning age discrimination into health policy. New England Journal of Medicine, 1984, 10, 1294–301.
5. Berwick, D. M., Cretin, S., Keeler. E. B. Cholesterol, children, and heart disease: An analysis of alternatives. New York: Oxford University Press, 1980.
6. Boon, R. A., Roberts, D. F. The social impact of haemophilia. Journal of Biosocial Science, 1970, 2, 237–64.
7. Braunwald, E., Isselbacher, K. J., Petersdorf, R. G., et al. (eds.), Harrison's principles of internal medicine, 11th ed. New York: McGraw-Hill Book Company, 1987.
8. Bronks, I. G., Blackburn, E. K. A socio-medical study of haemophilia and related states. British Journal of Preventative Social Medicine, 1968, 22, 68–72.
9. Butler, J. A., Budetti, P., McManus, M. A., et al. Health care expenditures for children with chronic illnesses. In N. Hobbs and J. M. Perrin. Issues in the care of children with chronic illness. San Francisco: Jossey-Bass Publishers, 1985.
10. Cook, T. D., Campbell. D. T. Quasi-experimentation: Design and analysis issues for field settings. Boston: Houghton-Mifflin, 1979.
11. Dinkel, R. H. Cost-benefit analysis: A helpful tool for decision makers? Health Policy, 1985, 4, 321–30.
12. Eyster, M. E., Lewis, J. H., Shapiro, S. S., et al. The Pennsylvania Hemophilia Program 1973–1978. American Journal of Hematology, 1980, 9, 277–86.
13. Fundenberg, H. H. The dollar benefits of biomedical research: A cost analysis. Journal of Laboratory and Clinical Medicine, 1972, 79, 353–63.
14. Griffiths, A. Cost-effectiveness and cost-benefit analysis of health services: The methodology and its application. Health Policy, 1988, 9, 251–65.
15. Hernandez, J., Gray, D., Lineberger, H. P. Social and economic indicators of well-being among hemophiliacs over a 5-year period. General Hospital Psychiatry, 1989, 11,241-47.
16. Hilgartner, M. W., Aledort, L., Giardina, P. J. V. Thalassemia and hemophilia. In N. Hobbs and J. M. Perrin (eds.), Issues in the care of children with chronic illness. San Francisco: Jossey-Bass Publishers, 1985.
17. Hilgartner, M. W., Sergis, E. Current therapy for hemophiliacs: Home care and therapeutic complications. Mount Sinai Journal of Medicine, 1977, 44, 316–31.
18. Ingram, G. I. C., Dykes, S. R., Creese, A. L., et al. Home treatment in haemophilia: Clinical, social and economic advantages. Clinical and Laboratory Haematology, 1979, 1, 13–27.
19. Johnson, R. E., Lawrence, D. N., Evatt, B. L., et al. Acquired immunodeficiency syndrome among patients attending hemophilia treatment centers and mortality experience of hemophiliacs in the United States. American Journal of Epidemiology, 1985, 121, 797–810.
20. Jones, P. K., Ratnoff, O. D. The changing prognosis of classic hemophilia (factor VIII deficiency). Annals of Internal Medicine, 1991, 114, 641–48.
21. Klarman, H. E. Application of cost-benefit analysis to health systems technology. Journal of Occupational Medicine, 1974, 16, 172–86.
22. Koop, C. E. Surgeon General's report: children with special health care needs, campaign '87, commitment to family centered coordinated care for children with special health care needs, Rockville, MD: U.S. Department of Health and Human Services, 1987.
23. Levine, P. H. Delivery of health care in hemophilia. Annals of the New York Academy of Sciences, 1975, 240, 201–07.
24. Linney, D. R.,Lazerson, J. Hemophilia: Cost considerations for prescribing therapeutic materials. Transfusion, 1979, 19, 57–59.
25. Markova, I., Forbes, C. D., Rowlands, A., et al. The haemophilic patient's self-perception of changes in health and life-style arising from self-treatment. International Journal of Rehabilitation Research, 1983,6, 11–18.
26. McMillan, C. W., Greene, W. B., Blatt, P. M., et al. The management of musculoskeletal problems in hemophilia. Instructors Course Lectures, 1983, 32, 210–16.
27. Newacheck, P. W. The costs of caring for chronically ill children. Business and Health, 1987, 4, 18–24.
28. Perry, M. C. Mortality and morbidity in hemophilia. Missouri Medicine, 1984,81,133-35.
29. Roberts, H. R. Hemophiliacs with inhibitors: Therapeutic options (editorial). New England Journal of Medicine, 1981, 305, 757–58.
30. Rosendaal, F. R., Smith, C., Briet, E. Hemophilia treatment in historical perspective: A review of medical and social developments. Annals of Hematology, 1991, 62, 5–15.
31. Rosendaal, F. R., Varekamp, I., Smith, C., et al. Mortality and causes of death in Dutch haemophiliacs, British Journal of Haematology, 1989, 71, 71–76.
32. Rossi, P. H., Freeman, H. E., Wright, S. R. Evaluation: A systemic approach, Beverly Hills, Sage Publications, Inc., 1979.
33. Salkever, D. S. Parental opportunity costs and other economic costs of children's disabling conditions. In N. Hobbs and J. M. Perrin (eds.), Issues in the care of children with chronic illness. San Francisco: Jossey-Bass Publishers, 1985.
34. Sjamsoedin, L. J. M., Heijnen, L., Mauser-Bunschoten, E. P., et al. The effect of activated prothrombin-complex concentrate (FEIBA) on joint and muscle bleeding in patients with hemophilia A and antibodies to factor VIII. New England Journal of Medicine, 1981, 305, 717–21.
35. Smith, C., Rosendaal, F. R., Varekamp, I., et al. Physical condition, longevity, and social performance of Dutch haemophiliacs, 1972–1985. British Medical Journal, 1989, 298, 235–38.
36. Smith, P. S., D. S. Goldman. Care of the young hemophiliac. American Journal of Pediatric Hematology and Oncology, 1985,7, 165–74.
37. U.S. Bureau of Labor Statistics. No. 730. Annual percent change in selected price indexes: 1960 to 1986. Monthly Labor Review. In U.S. Bureau of the Census, Statistical Abstract of the United States: 1988, 108th ed. Washington, DC: Government Printing Office, 1987.
38. Weighton, W. Mortality in hemophiliac populations. Transactions of the Association of Life Insurance Medical Directors of America, 1982, 66, 129–229.
39. Weinstein, M. C., Fineberg, H. V. Clinical Decision Analysis. Philadelphia: W. B. Saunders Company, 1980.
40. Weinstein, M. C., Stason. W. B. Foundations of cost-effectiveness analysis for health and medical practices. New England Journal of Medicine, 1977, 296, 716–21.